Evista, Keoxifene, Keoxifene Hydrochloride, LY 139481, LY 156758, LY-139481, LY-156758, LY139481, LY156758, Raloxifene, Raloxifene HCl, Raloxifene Hydrochloride
| Name | Raloxifene hydrochloride | ||
| PubChem CID | 54900 | ||
| Molecular Weight | 510.0g/mol | ||
| Synonyms |
Evista, Keoxifene, Keoxifene Hydrochloride, LY 139481, LY 156758, LY-139481, LY-156758, LY139481, LY156758, Raloxifene, Raloxifene HCl, Raloxifene Hydrochloride |
||
| Formula | C₂₈H₂₈ClNO₄S | ||
| SMILES | C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl | ||
| InChI | 1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H | ||
| InChIKey | BKXVVCILCIUCLG-UHFFFAOYSA-N | ||
| CAS Number | 82640-04-8 | ||
| ChEMBL ID | CHEMBL1116 | ||
| ChEBI ID | CHEBI:50740 | ||
| KEGG ID | D02217 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | WuZhuYu | ||
| Use Part | Fruit | ||
| Flavor | Pungent; Bitter | ||
| Meridian Tropism | Liver; Spleen; Stomach | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Sapindales
-->Family: Rutaceae
-->Genus: Tetradium
-->Species: Tetradium ruticarpum
|
||
| Pair Name | Raloxifene hydrochloride, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Up-regulation | Phosphorylation | BCL2 | hsa596 |
| Up-regulation | Phosphorylation | CCNB1 | hsa891 | |
| Up-regulation | Phosphorylation | CDC25C | hsa995 | |
| Up-regulation | Phosphorylation | CDC25C | hsa995 | |
| Up-regulation | Phosphorylation | CDK1 | hsa983 | |
| In Vitro Model | BCaP-37 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0164 |
| Bats-72 | Bats-72 was screened from ER- human breast cancer cell line BCap37 by time-stepwise and dose-stepwise increment exposure of paclitaxel as described previously | / | N.A. | |
| Bads-200 | Bads-200 was screened from ER- human breast cancer cell line BCap37 by time-stepwise and dose-stepwise increment exposure of paclitaxel as described previously | / | N.A. | |
| Result | Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells | |||
